Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 3:27 AM
Ignite Modification Date:
2025-12-25 @ 3:27 AM
NCT ID:
NCT05233605
Eligibility Criteria:
Inclusion Criteria:
* Adult patient (age ≥ 18 years at the time of inclusion) under 75 years old
* COVID-19 infection documented by PCR test performed on a nasopharyngeal swab or from a bronchoalveolar sample
* High affinity homozygous TPSO genotyping for \[18F\] -DPA-714 or heterozygous intermediate affinity for \[18F\] -DPA-714
* Patient who was hospitalized in intensive care for ARDS after COVID infection which required mechanical ventilation and deep sedation for at least 24 hours
* Patient alive at 24 months (+ 24 months) after discharge from intensive care
* Signature of informed consent
* Patient affiliated to a National French social security system, excluding (French) State Medical Aid (SMA)
For the group of patients exposed to dexmedetomidine:
* Administration of dexmedetomidine for at least 24 hours during intensive care hospitalization
For the group of patients not exposed to dexmedetomidine:
* No administration of dexmedetomidine during intensive care hospitalization
Exclusion Criteria:
* Protected adult (under legal protection, guardianship or curatorship)
* Pregnancy or breast-feeding
* Contraindication to PET or MRI examination
* Severe renal impairment (creatinine clearance \<30 mL / min)
* Contraindication to the administration of the radiopharmaceutical agent \[18F\]-DPA-714
* Serious neurological history at admission to intensive care:
* Stroke
* Severe head trauma
* Dementia with loss of autonomy
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
74 Years
Study:
NCT05233605
Study Brief:
Protocol Section:
NCT05233605